Record mula sa primary source

MateryalNaisumite ang aplikasyon

enGene nagpaplano ng 12-buwang CR data at pre-BLA FDA meeting para sa detalimogene sa 2H 2026

The company will await 12-month complete response and durability data from LEGEND Cohort 1 before engaging the FDA in 2H 2026 to discuss initiating a BLA submission for detalimogene. Additional LEGEND cohorts (2a, 2b, 3) have been paused as part of a 50% workforce reduction to conserve cash for the planned BLA and pre-commercial activities.

Mahahalagang fact

Na-file
Hun 15, 2026, 01:14 PM
Kaganapan
Naisumite ang aplikasyon
Direksyon
Neutral
Kumpanya
ENGNenGene
Pinagmulan
SEC 8-K
Kumpiyansa
May source
CR anumang oras
54% (95% CI: 45%, 63%)
Rate ng pag-unlad
3.2%
Pagkaantala dahil sa trae
2.4%
Pagtigil dahil sa trae
2.4%

Sipi mula sa source

EX-99.1 2 engn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 enGene Reports Second Quarter 2026 Financial Results and Provides Business Update 12-month complete response data from LEGEND pivotal cohort and subsequent FDA engagement planned for 2H 2026 Initiation of Biologics License Application (BLA) filing for detalimogene planned for 2H 2026 First patients enrolled in surfactant plus detalimogene cohort Approximately 50% reduction in force to streamline operations and preserve cash to focus on BLA and precommercial activities Well capitalized with cash, cash equivalents and marketable securities of $285 million BOSTON & MONTREAL, June 15, 2026  – enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced its fina

SEC 8-K

Higit pa tungkol sa asset na ito

Okt 13, 2026
12:00 PM
ENGNenGene

enGene Magho-host ng KOL Webinar tungkol sa Surfactant Rinse + Detalimogene para sa NMIBC sa Oktubre 15, 2026

Presentasyon sa kumperensyaPress release ng kumpanya
Ago 11, 2026
08:03 PM
ENGNenGene

enGene: LEGEND pivotal cohort 12-month data at BLA filing inaasahang 2H 2026

Presentasyon sa kumperensyaSEC 8-K
Mar 9, 2026
11:04 AM
ENGNenGene

enGene: plano ng pag-update sa pivotal cohort ng LEGEND sa medical conference sa tagsibol ng 2026

Presentasyon sa kumperensyaSEC 8-K
enGene nagpaplano ng 12-buwang CR data at pre-BLA FDA meeting para sa detalimogene sa 2H 2026 | SimianX AI